Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.

Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ECOR
- Company electroCore, Inc.
- Price $9.55
- Changes Percentage -26.54
- Change -3.45
- Day Low $9.31
- Day High $11.73
- Year High $19.49
- Year Low $5.32
- Market Cap $63,566,615
- Price Avg 50 EMA (D) $16.01
- Price Avg 200 EMA (D) $10.27
- Exchange NASDAQ
- Volume 804,386
- Average Volume 145,355
- Open $11.73
- Previous Close $13
- EPS -1.59
- PE -6.01
- Earnings Announcement 2025-05-06 10:59:00
- Shares Outstanding $6,656,190
Company brief: ELECTROCORE, INC. (ECOR )
- Healthcare
- Medical - Devices
- Mr. Daniel S. Goldberger
- https://www.electrocore.com
- US
- N/A
- 06-22-2018
- US28531P2020
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
ECOR Corporation News
electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript
seekingalpha.com -- electroCore, Inc. (NASDAQ:ECOR ) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Par...
electroCore Announces Full Year 2024 Financial Results
globenewswire.com -- Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM in the United States Department of Vete...